Betta Pharmaceuticals Co. Ltd. has described hypoxia-inducible factor-2α (HIF-2α; EPAS1) inhibitors reported to be useful for the treatment of Von Hippel-Lindau disease, cancer, autoimmune disease and inflammatory disorders.